Similar articles

• Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.

  Stone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, Cox DA, Pocock SJ, Ware JH, Feit F, Colombo A, Manoukian SV, Lansky AJ, Mehran R, Moses JW; Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial investigators. Stone GW, et al. Lancet. 2007 Mar 17;369(9565):907-19. doi: 10.1016/S0140-6736(07)60450-4. Lancet. 2007. PMID: 17368152 Clinical Trial.
• Accounting for ACUITY.

  Bittl JA. Bittl JA. N Engl J Med. 2006 Nov 23;355(21):2249-50. doi: 10.1056/NEJMe068227. N Engl J Med. 2006. PMID: 17124024 No abstract available.
• Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial.

  Stone GW, Ware JH, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, Feit F, Colombo A, McLaurin BT, Cox DA, Manoukian SV, Fahy M, Clayton TC, Mehran R, Pocock SJ; ACUITY Investigators. Stone GW, et al. JAMA. 2007 Dec 5;298(21):2497-506. doi: 10.1001/jama.298.21.2497. JAMA. 2007. PMID: 18056903 Clinical Trial.
• Direct thrombin inhibitors for percutaneous coronary intervention in the current era of platelet glycoprotein IIb/IIIa inhibition.

  Reginelli JP, Chew D. Reginelli JP, et al. J Interv Cardiol. 2002 Apr;15(2):141-6. doi: 10.1111/j.1540-8183.2002.tb01046.x. J Interv Cardiol. 2002. PMID: 12063809 Review. No abstract available.
• Debate of adjunctive pharmacology for percutaneous coronary intervention: thrombin inhibitors and clopidogrel are enough.

  Yehudai L, Feit F. Yehudai L, et al. J Interv Cardiol. 2006 Oct;19(5):464-9. doi: 10.1111/j.1540-8183.2006.00180.x. J Interv Cardiol. 2006. PMID: 17020572 Review.